Drugs / 12ATC
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00016055 | Nov 2000 → ? | cutaneous melanoma | St. Luke's Medical Center | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00030342 | Nov 2001 → Oct 2007 | colorectal cancer, kidney cancer | St. Luke's Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 12ATC | “The PBMC are treated ex vivo to form interleukin-12-primed activated T cells (12ATC).” NCT00030342 ↗1“interleukin-12-primed activated T cells (12ATC)” NCT00016055 ↗ |
| Known as | interleukin-12-primed activated T cells | “The PBMC are treated ex vivo to form interleukin-12-primed activated T cells (12ATC).” NCT00030342 ↗1“interleukin-12-primed activated T cells (12ATC)” NCT00016055 ↗ |
| Modality | Cell therapy | “interleukin-12-primed activated T cells (12ATC)” NCT00016055 ↗ |
| Route | Intravenous | “12ATC IV over 15-30 minutes” NCT00016055 ↗ |